-
Villeneuve teases James Bond casting at Los Angeles museum gala
-
Thames Water seeks to delay £12bn in debt repayments
-
Nottinghamshire launches specialist rural crime policing team
-
Newark boxing gym expands alternative education programme
-
China confirms talks over possible Xi-Putin-Trump summit
-
Democrats consider impeachment drive against Defence Secretary Hegseth
-
Rail journey offers a slower route to a Berlin city break
-
Energy bill plan could use HMRC income data to target support
-
Arsenal control title race as Manchester United fall into bottom three
-
Business owner earning £6,000 a month tackles £70,000 debt
-
Suspected Krakow gunman dies after attack that killed six
-
Nvidia chief faces inquiry after disclosing affair with suspected Chinese agent
-
Carrick backs Dalot after hostile reception from Manchester United fans
-
Comet returns as online electrical marketplace 14 years after collapse
-
Fire in Northern China Apartment Building Kills 14
-
Solihull Hospital Performs First Robotic-Assisted Gynaecological Cancer Surgeries
-
Apple’s 20th Anniversary iPhone to Skip Action Button for Camera Control Integration
-
Nvidia CEO Jensen Huang Admits Infidelity Amid Spy Investigation
-
Family of Woman Who Died at Voting Station Condemns Official Silence
-
Ted Scheinman’s Journey Through Depression and Electroconvulsive Therapy
-
Karen Wazen Launches First Standalone Boutiques in Cairo
-
Phoenix Symphony Resumes Performances Amid Financial Uncertainty
-
A Holiday-Season Moment for Penny-Stock Followers and Microcap Visionaries as Elektros Moves Its EV Patent Forward
-
Jericho Energy Ventures to Participate in Cantor Convergence 4th Annual Crypto and AI Infrastructure Conference
-
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
-
United States Antimony Corporation Announces Webcast Time set for Thursday, November 12, 2026 at 4:15 PM ET to Report on Third Quarter and Nine Months Ended September 30, 2026 Financial and Operating Results
-
Tectonic Metals Adds Mine Development and Alaska Native Partnership Leaders Ahead of 2027 Mineral Resource Estimate and Preliminary Economic Assessment
-
Ai4 Celebrates Successful Debut of Applied AI Research Conference (AAIRC), Bridging Academic Research and Industry Innovation
-
Releaf Unveils UK-first THCV for Weight Management
-
Gabriel Provides Corporate Update
-
Hancock Health Expands Robot Specimen Delivery to Parkway Building, Adding Scheduled and On-Demand Runs to the Lab
-
AsiaFIN's Insite MY Holdings and MENA Insite MY Sign Distributorship Agreement and Announce Second Bank Customer in Saudi Arabia
-
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
-
Nextech3D.ai Closes $720,000 Management-Led Private Placement
-
CoTec Holdings Corp. Notes HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
-
Silver Storm Reports Concentrate Deliveries from La Parrilla
-
Ispire Technology Inc. Reports First Quarter Fiscal Year 2027 Financial Results
-
HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
-
Hillcrest and Equipmake Sign Definitive Agreement to Jointly Develop and License ZVS Inverter Technology for Heavy-Duty Electric Vehicles
-
Tintina Mines Intersects 460m at 0.50% CuEq at the Dos Amigos Copper-Gold Project in Chile
-
Pace Launches Three-Business-Day Culture-Based 'L. pneumophila' Testing
-
Opti Digital Launches NEXA, an AI-Powered Intelligence Layer
-
DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 09
-
Making Your Home Safer for Aging Parents: Accessibility Renovations That Add Value
-
New 401k Gold IRA Investment Guide Explains the Best Way to Invest in Gold for Retirement (2026 Update)
-
Eylsia Nicolas Launches Global "Wake Me Up" Franchise After Surpassing 100 Million Meta Views in One Week
-
AELF Acquires Two Airbus A330 Aircraft on Lease to Wamos Air
-
CCA Industries, Inc. Reports Results of Operations for the Quarter and Nine Months ended August 31, 2026
-
Penny Stock Enthusiasts, Microcap Visionaries & Institutional Investors: A Moment to Watch as Elektros Works to Advance Its Patented EV Technology Toward a First Prototype
What is microRNA? Nobel-winning discovery explained
The Nobel Prize in Medicine was awarded on Monday to two US scientists for discovering microRNA, a previously unknown type of genetic switch which is hoped can pave the way for new medical breakthroughs.
But while several treatments and tests are under development using microRNAs against cancer, heart disease, viruses and other illnesses, none have actually yet reached patients.
And the world paid little attention when the new Nobel laureates Victor Ambros and Gary Ruvkun revealed their discovery decades ago, thinking it was just "something weird about worms", Cambridge University geneticist Eric Miska told AFP.
Here is an explainer about how exactly these tiny genetic switches work inside our bodies.
- What is microRNA? -
Each cell in the human body has the same set of instructions, called DNA. Some turn into brain cells, while others become muscles.
So how do the cells know what to become? The relevant part of the DNA's instructions is pointed to via a process called gene regulation.
Ribonucleic acid (RNA) normally serves as a messenger. It delivers the instructions from the DNA to proteins, which are the building blocks of life that turn cells into brains -- or muscles.
Miska gave the example of the messenger RNA vaccines rolled out against Covid-19 during the pandemic, which insert a message with new instructions to build proteins that block viruses.
But the two new Nobel winners Ambros and Ruvkun discovered a whole new type of gene regulator that had previously been overlooked by science.
Rather than being the messenger which relays information, microRNA instead acts as a switch to turn other genes off and on.
"This was a whole new level of control that we had totally missed," said Miska, who has worked on microRNA for two decades, including with the new Nobel laureates.
"The discovery of microRNAs brought an additional level of complexity by revealing that regions that were thought to be non-coding play a role in gene regulation," French researcher Benoit Ballester told AFP.
- What did the Nobel winners do? -
Back in the 1980s, Ambros and Ruvkun had been working separately on how genes interact in one-millimetre-long roundworms called C.elegans.
When they compared their work, it led to the discovery of microRNA. Ambros revealed the finding in a 1993 paper.
"Nobody really paid much attention," Miska said, explaining that most scientists at the time thought it only applied to worms.
Then in 2000, Ruvkun published research showing that microRNA is present right across the animal kingdom, including in humans and even some viruses.
"This was not just something weird that worms do, but in fact all animals and plants are totally dependent for development and normal function on them," Miska said.
More than a thousand genes that respond to microRNAs are now believed to be in the human body.
- How could this help us? -
There are numerous new treatments and tests using microRNA that are undergoing trials but none have been made widely available.
"Though there are no very clear applications available yet in microRNAs, understanding them, knowing that they exist, understanding their counter-regulatory networks, is always the first step," the Karolinska Institute's Gunilla Karlsson Hedestam told journalists in Stockholm.
MicroRNAs are particularly promising for fighting cancer because some of these switches "act as a tumour suppressor, so they put a brake on cells dividing inappropriately," Miska said.
Others, meanwhile, induce "cells to divide, which can lead to cancer", he added.
Because many viruses use microRNAs, several antiviral drugs are at varying stages of development, including for hepatitis C.
One complicating factor has been that microRNAs can be unstable.
But scientists also hope they can be used as a test called a "biomarker", which could reveal what type of cancer a patient could be suffering from, for example.
- What next? -
It also appears probable that microRNAs could be involved in the evolution of our species, Miska said.
While human brains are difficult to study, Miska hoped future research will discover more.
O.Gutierrez--AT